The most common type of muscular dystrophy, Duchenne muscular dystrophy (DMD), affects 1 of every 3500 live male births. Currently, the disease is poorly understood and there is no cure-only treatments such as prednisone to control symptoms. Previous research with DMD has utilized a number of model organisms, including mice, dogs, and nematodes. Each organism has its challenges; for mice and dogs, challenges include limited screening ability and ethical issues. While C. elegans seems like an ideal platform for testing compounds and improving understanding of mechanisms relating to dystrophin, researchers have not been able to obtain a DMD-like phenotype in dystrophin mutants cultured in standard environments unless using a strain with a secondary mutation. This background mutation raises some questions about the similarity of the muscle degeneration mechanism to that of humans with DMD. Thus, there is a great need to establish an assay that can detect muscular degradation and measure the effects of drugs in dystrophin-deficient mutants. For this reason we have developed nematode strength as a phenotype of interest in strains with muscular mutations. For this study, we utilized two dystrophin deficient strains:
dys-1(
cx18), the most commonly utilized mutant in C. elegans DMD studies, and
dys-1(
eg33). Both strains are reported as having nonsense mutations, although the stability and interactions of the resulting proteins are unknown. Using our NemaFlex platform, we measured the strength of the nematodes on days 3, 5, and 7 of life. While the
cx18 allele did not confer discernible differences from the wild-type control at any time point, the
eg33 allele was associated with weakness on days 5 and 7 when post-developmental muscle degeneration becomes more apparent. We then checked if prednisone or melatonin had any effect on the strengths of the worms. As expected, treated wild-type animals and the
cx18 animals were not discernible from their non-treated counterpart, whereas the
eg33 mutants improved their strength significantly under all treatments. Furthermore, some treatments returned the strength of the
eg33 mutants to wild-type levels. These results suggest that there is an interesting difference between the two mutants that requires further investigation. The ability to screen drugs for the effect on nematode strength offers a couple of promising outcomes. Using this assay, we may be able to discover new pharmacological compounds that improve strength, offering more options for treating DMD in humans. Moreover, combining our assay with analyses of cellular components in the nematode could offer additional insight on the genetic mechanisms behind muscular dystrophy.